
Tadalafil (Research)
PDE5 inhibitor (research liquid).
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
PDE5 inhibitor equivalent to Cialis. Erectile function. Long half-life.
Mechanism · Phosphodiesterase 5 (PDE5) inhibitor. Note: small molecule, NOT peptide.
Best for. Not for.
Best for
- Erectile dysfunction (FDA Cialis 2003)
- BPH (FDA Cialis 2011)
- Pulmonary HTN (FDA Adcirca 2009)
- Long half-life of 36 hours. Daily or on-demand dosing
Not for
- Nitrate / α-blocker concurrent (severe hypotension)
- Unstable angina / recent MI
- Severe hepatic / renal impairment
- Note: small molecule, not a peptide. Research-liquid disclosure
Mechanism, dose, ramp, risk.
- Mechanism
- PDE5 inhibitor (Cialis active). Long half-life ED research compound.Source · PEPVERA editorial
- Target dose
- 5-20 mg, oral.Source · PEPVERA editorial
- Ramp
- On demand or daily.Source · PEPVERA editorial
- Risks
- Headache, BP drop with nitrates.Source · PEPVERA editorial
Compared to its siblings.
Tadalafil (Research)
PDE5 inhibitor equivalent to Cialis. Erectile function. Long half-life.
Pros
- · FDA Cialis 2003 approval with 20+ year evidence base.
- · Peripheral PDE5 mechanism for users non-responsive to central pathways.
- · Generic available since 2018.
Cons
- · No central libido pathway; PT-141 Vyleesi 2019 acts on MC4R for non-responders to PDE5.
PT-141 (Bremelanotide)
Central libido (MC4R). An alternative for users non-responsive to PDE5 inhibitors.
Pros
- · FDA Vyleesi 2019
- · Central pathway
Cons
- · Female HSDD label (male ED off-label)
See PT-141 (Bremelanotide) →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
5-20 mg, oral.
Initiation
Week 3–4
5-20 mg, oral.
Signal emerges
Week 5–8
5-20 mg, oral.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.
drive · VII
Tadalafil (Research) · 5mg